Please login to the form below
NICE
This page shows the latest NICE news and features for those working in and with pharma, biotech and healthcare.
NICE recommends Sanofi and Regeneron’s Libtayo for advanced CSCC
NICE’s decision was based on positive results from the EMPOWER-CSCC-1 trial. ... NICE first recommended that Libtayo should be made available through the Cancer Drugs Fund (CDF) in 2019.
Latest news
-
Almirall and Inserm Transfert to develop innovative vitiligo treatments
The collaboration agreement, signed by Inserm Transfert on behalf of Inserm, Centre Hospitalier Universitaire of Nice and University of Nice Côte d’Azur, aims to identify and develop a novel class
-
NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer
2019. NICE has recommended routine access to this treatment following an assessment of additional efficacy and safety data for Imfinzi in these patients. ... The positive recommendation by NICE should increase clinician confidence in using a combination
-
NHS to offer two new treatments for drug-resistant superbugs as part of a new subscription-style payment plan
NHS England, the National Institute for Health and Care Excellence (NICE) and the UK Department of Health have concluded an assessment of Pfizer’s Zavicefta (ceftazidime with avibactam) and Shionogi’s ... Incentivising pharma companies is crucial,
-
Amgen and UCB’s Evenity recommended by NICE for severe osteoporosis
Amgen and UCB’s Evenity (romosozumab) has been recommended for use by the NHS in England and Wales by the National Institute for Health and Care Excellence (NICE). ... Northern Ireland then followed and approved Evenity in January 2021. “NICE’s
-
NICE recommends Amgen’s Lumykras for non-small-cell lung cancer
The National Institute for Health and Care Excellence (NICE) has issued a final appraisal document recommending Amgen’s Lumykras (sotorasib) for treatment use within the Cancer Drugs Fund. ... NICE’s decision to grant a recommendation for Lumykras
More from news
Approximately 417 fully matching, plus 837 partially matching documents found.
Latest Intelligence
-
Health technology assessments: understanding the global landscape and considerations for drug development
The National Institute for Health and Care Excellence (NICE) in the UK has long used cost- effectiveness assessments as the centre of its HTA, price and reimbursement process.
-
Mapping patient pathways with a focus on patient-centricity: the role of medical education
You only need look at the National Institute for Health and Care Excellence (NICE) pathways in adult Type 2 Diabetes (T2D) to see how many specialists are involved, including the diabetologist,
-
The power of the patient influencer
They may be advocating for their fellow patients behind the scenes, lobbying NICE for access to medicines, or publicising fundraising efforts via their local media.
-
How early-stage clinical research is facilitating the new wave of personalised medicines
For example, the UK health technology appraiser, NICE, is undergoing a review of its methodology to ensure that it can be more flexible in evaluating complex innovations such as personalised medicines.
-
Patient diversity in clinical trials needs to be centre stage
This is a strong position to adopt and it’s good to see NICE and the EMA now want patient experience data.”.
More from intelligence
Approximately 11 fully matching, plus 133 partially matching documents found.
Latest appointments
-
NICE looks internally for new chief executive
He was appointed in April 1999 when NICE was first established under Tony Blair’s ‘New Labour’ government. ... I am delighted that Gill has been appointed as NICE’s next chief executive.
-
Professor Carole Longson moves from NICE to the ABPI
The Association of the British Pharmaceutical Industry (ABPI) has attracted Professor Carole Longson away from the National Institute for Health and Care Excellence (NICE) to be its new chief scientific officer, ... She most recently spent the 18 years
-
New health ministers and re-appointments after reshuffle
Freeman's role is also tied into the Department for Business, Innovation and Skills and includes expanded responsibility for the Cancer Drugs Fund, NICE and MHRA, research and development, issues around
-
Virgo Health Education appoints new senior team
She has over 15 years' experience working in medical education and is a member of the ISMPP Ethics Committee, the NICE Implementation External Reference Group and part of the Royal Berkshire
-
Former NICE chair Sir Michael Rawlins to lead MHRA
Care Excellence (NICE) from its formation in 1999 to his departure last year.
More from appointments
Approximately 4 fully matching, plus 10 partially matching documents found.
Latest from PMHub
-
Could femtech be the answer to the gender health gap?
37. While the app is approved for sale in the UK and can be advertised to the public, NICE still argues that there is not yet sufficient evidence for the app ... Published September 10, 2018. Accessed November 4, 2021. Wilkinson E. NICE: More evidence
-
Top 10 Tips for “Virtualizing” In-person Meetings
While Pharma was already slowly pivoting towards virtual events as a substitute for, or supplement to, in-person meetings, COVID-19 quickly changed virtual events from a nice-to-have to
-
What do NHS changes and the Life Sciences Vision mean for medicines?
expensive treatment (even going outside of NICE guidance) because of this prioritised aspect of product value.
-
Abbie's (associate copywriter) first 6-months at COUCH Health
Yet, it’s so nice that I’ve not felt disconnected from the company at all, considering most of my interaction with the team has been online.
-
Why it’s in everyone’s interest the Women’s Health Strategy for England succeeds
5. This strategy isn’t just a nice to have, a way for the Government to appeal to women voters.
More from PMHub
Approximately 2 fully matching, plus 56 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Health Psychologist, London
-
Highly competitive salary
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
-
Head of Health Psychology, London
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientists discover new approach to treat brain tumours
- AstraZeneca’s COVID-19 vaccine receives EMA approval for use as third-dose booster
- Takeda and Daiichi Sankyo collaborate to create wearable device
- NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer
- Sanofi and Regeneron receive FDA approval for eosinophilic oesophagitis treatment
- UICC launches global ATOM Coalition to increase access to essential cancer medicines
- Improving Drug Access with Data Analytics
- How digital health is changing the relationship between patients and health providers | OPEN Health
- NICE recommends Sanofi and Regeneron’s Libtayo for advanced CSCC
- Roche’s Polivy receives EC approval for lymphoma therapy
- Eli Lilly announces $2.1bn investment in new manufacturing sites
- How ‘Greenwashing’ accusations could delay the very changes its supporters demand
Latest intelligence
- How ‘Greenwashing’ accusations could delay the very changes its supporters demand
- Are shouts of companies ‘greenwashing’ to provide a façade of environmental and ethical respectability causing more harm than good? Or should we call out practices that we believe are papering...
- What does the future hold for clinical trial recruitment?
- The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
- When is an agency not an agency?
- The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
